Wells Fargo & Company Imara Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$3.73 - $5.2 $11 - $15	3 Added 3.19%	97 $0
Q3 2022 Nov 14, 2022	BUY	$1.11 - $2.42 $11 - $24	10 Added 11.9%	94 $0
Q2 2022 Aug 12, 2022	BUY	$0.99 - $1.87 $5 - $11	6 Added 7.69%	84 $0
Q3 2021 Nov 15, 2021	BUY	$4.08 - $7.83 $195 - $375	48 Added 160.0%	78 $0
Q2 2021 Aug 16, 2021	SELL	$6.78 - $9.04 $15,641 - $20,855	-2,307 Reduced 98.72%	30 $0
Q1 2021 May 13, 2021	SELL	$8.18 - $23.98 $12,507 - $36,665	-1,529 Reduced 39.55%	2,337 $20,000
Q4 2020 Feb 09, 2021	BUY	$15.81 - $29.0 $35,493 - $65,105	2,245 Added 138.49%	3,866 $85,000
Q3 2020 Nov 05, 2020	SELL	$18.75 - $28.58 $21,337 - $32,524	-1,138 Reduced 41.25%	1,621 $33,000
Q2 2020 Aug 13, 2020	BUY	$15.6 - $54.87 $43,040 - $151,386	2,759 New	2,759 $76,000

104K

170K

Ticker IMRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,287,300
Market Cap $552M
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.